

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

TRIAL

A Study of LN-144 in People With Metastatic Melanoma to the Brain

NCT ID: NCT05640193 Phase: PHASE1 Sponsor: Memorial Sloan Kettering Cancer Center Status: Active Not Recruiting

SUMMARY

This is an open label study evaluating lifileucel (LN-144) in patients with melanoma brain metastases.

KEY ELIGIBILITY CRITERIA

- 1. Metastatic melanoma with asymptomatic brain metastases
- 2. At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to generate TIL
- 3. Must be e 18 years of age at time of consent
- 4. ECOG performance status of 0-1 and estimated life expectancy of e 3 months
- 5. Adequate hematologic parameters and organ function
- 1. Received organ allograft, except kidney transplant, or prior cell transfer therapy including TIL and CAR-T therapies
- 2. Ongoing grade 2-4 toxicity from prior immunotherapy (excluding endocrine, ocular toxicity or vitiligo)
- 3. History of hypersensitivity to any component or excipient of lifileucel or other treatment regimen drugs
- 4. Symptomatic brain metastases
- 5. Chronic systemic steroid therapy of \geq 10 mg/day

Total sites: 1 | 0 currently recruiting